Thus, a high degree of overlap between CSF3R and CEBPA mutations may facilitate an in-depth understanding of the role of CSF3R in the pathogenesis and prognosis of AML patients with CEBPAdm, and development of new targeted therapy, which will be discussed in a subsequent section. This evidence concerns the gene CEBPA and acute myeloid leukemia.